Cargando…

Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies

Antigen-binding fragments of antibodies specific to the tumor-associated ganglioside GD2 are well poised to play a substantial role in modern GD2-targeted cancer therapies, however, rapid elimination from the body and reduced affinity compared to full-length antibodies limit their therapeutic potent...

Descripción completa

Detalles Bibliográficos
Autores principales:	V. Kholodenko, Irina, V. Kalinovsky, Daniel, V. Svirshchevskaya, Elena, I. Doronin, Igor, V. Konovalova, Maria, V. Kibardin, Alexey, V. Shamanskaya, Tatyana, S. Larin, Sergey, M. Deyev, Sergey, V. Kholodenko, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864547/ https://www.ncbi.nlm.nih.gov/pubmed/31653037 http://dx.doi.org/10.3390/molecules24213835

Ejemplares similares

Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment–Drug Conjugates Carrying Maytansinoids DM1 and DM4
por: Kalinovsky, Daniel V., et al.
Publicado: (2023)

Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells
por: Kalinovsky, Daniel V., et al.
Publicado: (2023)

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
por: Kalinovsky, Daniel V, et al.
Publicado: (2022)

RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype
por: Sorokin, Maxim, et al.
Publicado: (2020)

Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
por: Kholodenko, Irina V., et al.
Publicado: (2018)

Genetically Encoded Immunophotosensitizer 4D5scFv-miniSOG is a Highly Selective Agent for Targeted Photokilling of Tumor Cells In Vitro
por: Mironova, Kristina E., et al.
Publicado: (2013)

Self-Assembling Complexes of Quantum Dots and scFv Antibodies for Cancer Cell Targeting and Imaging
por: Zdobnova, Tatiana A., et al.
Publicado: (2012)

Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors
por: Sokolova, E. A., et al.
Publicado: (2015)

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
por: Cheng, Ming, et al.
Publicado: (2016)

Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020)

scFv Antibody: Principles and Clinical Application
por: Ahmad, Zuhaida Asra, et al.
Publicado: (2012)

Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library
por: Shams, Nasir, et al.
Publicado: (2022)

Generation and Characterization of an scFv Directed against Site II of Rabies Glycoprotein
por: Aavula, Shukra M., et al.
Publicado: (2011)

The Four-State Equilibrium Unfolding of a scFv Antibody Fragment
por: Pedroso, Idolka, et al.
Publicado: (2002)

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
por: Alric, Christophe, et al.
Publicado: (2018)

Nonspecificity in a nonimmune human scFv repertoire
por: Kelly, Ryan L., et al.
Publicado: (2017)

“Stapling” scFv for multispecific biotherapeutics of superior properties
por: Boucher, Lauren E., et al.
Publicado: (2023)

Construction of scFv Antibodies against the Outer Loops of the Microsporidium Nosema bombycis ATP/ADP-Transporters and Selection of the Fragment Efficiently Inhibiting Parasite Growth
por: Dolgikh, Viacheslav V., et al.
Publicado: (2022)

Ganglioside GD2 in reception and transduction of cell death signal in tumor cells
por: Doronin, Igor I, et al.
Publicado: (2014)

Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
por: Hutt, Meike, et al.
Publicado: (2018)

HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis
por: Sokolova, Evgeniya, et al.
Publicado: (2017)

A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats
por: Nannini, Francesco, et al.
Publicado: (2020)

Refolded scFv Antibody Fragment against Myoglobin Shows Rapid Reaction Kinetics
por: Song, Hyung-Nam, et al.
Publicado: (2014)

Cell-free eukaryotic systems for the production, engineering, and modification of scFv antibody fragments
por: Stech, Marlitt, et al.
Publicado: (2014)

Engineering an Anti-Transferrin Receptor ScFv for pH-Sensitive Binding Leads to Increased Intracellular Accumulation
por: Tillotson, Benjamin J., et al.
Publicado: (2015)

The effects of N-terminal insertion into VSV-G of an scFv peptide
por: Dreja, Hanna, et al.
Publicado: (2006)

Empowering scFv with effector cell functions for improved anticancer therapeutics
por: Zhang, Hongtao
Publicado: (2013)

Integrating scFv into xMAP Assays for the Detection of Marine Toxins
por: Shriver-Lake, Lisa C., et al.
Publicado: (2016)

Humanization and directed evolution of the selenium-containing scFv phage abzyme
por: Xu, Yan, et al.
Publicado: (2018)

Engineered Human Monoclonal scFv to Receptor Binding Domain of Ebolavirus
por: Densumite, Jaslan, et al.
Publicado: (2021)

Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity
por: Pelat, Thibaut, et al.
Publicado: (2009)

Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment
por: Girgis, Mark D, et al.
Publicado: (2011)

Cloning approach and functional analysis of anti-intimin single-chain variable fragment (scFv)
por: Menezes, Márcio A, et al.
Publicado: (2011)

In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe
por: Mazzocco, Claire, et al.
Publicado: (2016)

Recombinant production of the antibody fragment D1.3 scFv with different Bacillus strains
por: Lakowitz, Antonia, et al.
Publicado: (2017)

Expression of Single Chain Variable Fragment (scFv) Molecules in Plants: A Comprehensive Update
por: Satheeshkumar, Padikara Kutty
Publicado: (2020)

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants
por: Trebing, J, et al.
Publicado: (2014)

Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas
por: Kim, D-J, et al.
Publicado: (2002)

Production of scFv-Conjugated Affinity Silk Powder by Transgenic Silkworm Technology
por: Sato, Mitsuru, et al.
Publicado: (2012)

Early Detection of NSCLC with scFv Selected against IgM Autoantibody
por: Pedchenko, Tetyana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_u0pij6t11emcso7eod8viiq7m3